NTLA Stock Analysis: Intellia Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.986m USD | 12M Return: 13.6% | Charts, Fundamentals & Technical Analysis

Amyloidosis Treatment, Angioedema Treatment, Immuno-Oncology, Cell Therapy
Total Rating 16
Safety 28
Buy Signal -0.86
Biotechnology
Industry Rotation: +12.9
Market Cap: 1.99B
Avg Turnover: 88.3M
Risk 3d forecast
Volatility84.7%
VaR 5th Pctl14.2%
VaR vs Median2.11%
Reward TTM
Sharpe Ratio0.61
Rel. Str. IBD15
Rel. Str. Peer Group10.3
Character TTM
Beta1.976
Beta Downside2.178
Hurst Exponent0.474
Drawdowns 3y
Max DD86.23%
CAGR/Max DD-0.40
CAGR/Mean DD-0.58
EPS (Earnings per Share) EPS (Earnings per Share) of NTLA over the last years for every Quarter: "2021-06": -1.01, "2021-09": -0.97, "2021-12": -1.09, "2022-03": -1.96, "2022-06": -1.33, "2022-09": -1.49, "2022-12": -1.4, "2023-03": -1.17, "2023-06": -1.4, "2023-09": -1.38, "2023-12": -1.46, "2024-03": -1.12, "2024-06": -1.52, "2024-09": -1.34, "2024-12": -1.27, "2025-03": -1.1, "2025-06": -0.99, "2025-09": -0.92, "2025-12": -0.83, "2026-03": -0.81,
Last SUE: 0.53
Qual. Beats: 0
Revenue Revenue of NTLA over the last years for every Quarter: 2021-06: 6.55, 2021-09: 7.204, 2021-12: 12.854, 2022-03: 11.252, 2022-06: 14.03, 2022-09: 13.266, 2022-12: 13.573, 2023-03: 12.606, 2023-06: 13.594, 2023-09: 11.992, 2023-12: -1.917, 2024-03: 28.935, 2024-06: 6.957, 2024-09: 9.111, 2024-12: 12.874, 2025-03: 16.627, 2025-06: 14.245, 2025-09: 13.782, 2025-12: 23.017, 2026-03: 15.048,
Rev. CAGR: 12.39%
Rev. Trend: 59.3%
Last SUE: 0.14
Qual. Beats: 0

Warnings

Altman Z'' In Financial Distress Zone
Choppy
Below Avwap Earnings
Below Sma 200d

Tailwinds

Confidence

Seasonality 10.1 years of data

Jan -1.7% 8
Feb +6.3% 39
Mar -9.1% 37
Apr -8.2% 6
May +1.3% 2
Jun +17.7% 65
Jul +5.8% 23
Aug -0.7% 11
Sep -4.7% 35
Oct -6.4% 23
Nov +6.4% 20
Dec -14.2% 7

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: NTLA Intellia Therapeutics

Intellia Therapeutics is a clinical-stage biotechnology company developing curative genome editing therapies using CRISPR/Cas9 technology. The company operates a modular platform to advance both in vivo (delivered directly into the body) and ex vivo (cells edited outside the body) treatments.

Its lead in vivo candidates include nexiguran ziclumeran (NTLA-2001) for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. The pipeline also targets immuno-oncology, autoimmune diseases, and additional in vivo programs aimed at organs beyond the liver.

Intellia pursues a partnership-driven business model, collaborating with companies such as AvenCell, Kyverna, ONK Therapeutics, ReCode, Regeneron, SparingVision, and Rewrite to develop cell therapies and genomic medicines. As a clinical-stage biotech without approved products, the companys revenue is largely dependent on collaboration agreements and milestone payments rather than commercial product sales.

The company was incorporated in 2014 in Cambridge, Massachusetts, originally as AZRN, Inc., before adopting its current name. It trades on NASDAQ under the ticker NTLA.

Headlines to Watch Out For
  • NTLA-2002 hereditary angioedema Phase 3 data readout
  • Cash burn accelerates as pivotal trials enroll patients
  • CRISPR competition intensifies with Vertex and Editas approvals
  • Regeneron collaboration provides non-dilutive funding runway
Piotroski VR-10 (Strict) 0.0
Net Income: -394.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.48 > 0.02 and ΔFCF/TA -9.27 > 1.0
NWC/Revenue: 590.1% < 20% (prev 962.9%; Δ -372.8% < -1%)
CFO/TA -0.48 > 3% & CFO -363.2m > Net Income -394.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.10 > 1.5 & < 3
Outstanding Shares: last quarter (118.5m) vs 12m ago 14.48% < -2%
Gross Margin: -153.7% > 18% (prev 77.43%; Δ -231.2% > 0.5%)
Asset Turnover: 7.58% > 50% (prev 4.62%; Δ 2.95% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' -6.48
A: 0.51 (Total Current Assets 466.4m - Total Current Liabilities 76.4m) / Total Assets 758.8m
B: -3.54 (Retained Earnings -2.69b / Total Assets 758.8m)
C: -0.45 (EBIT TTM -394.6m / Avg Total Assets 872.5m)
D: 4.50 (Book Value of Equity 620.9m / Total Liabilities 137.8m)
Altman-Z'' = -6.48 = D
Beneish M -3.07
DSRI: 0.60 (Receivables 9.13m/10.5m, Revenue 66.1m/45.6m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.95 (AQ_t 0.24 / AQ_t-1 0.25)
SGI: 1.45 (Revenue 66.1m / 45.6m)
TATA: -0.04 (NI -394.6m - CFO -363.2m) / TA 758.8m)
Beneish M = -3.07 (Cap -4..+1) = AA
What is the price of NTLA shares?

As of July 16, 2026, the stock is trading at USD 13.04 with a total of 3,923,994 shares traded. Over the past week, the price has changed by -22.57%, over one month by -12.60%, over three months by -12.72% and over the past year by +13.59%.

Current recommended Stop Loss: 11.20 (which is 14.1% or 1.5 ATR below the current price).

Is NTLA a buy, sell or hold?

Intellia Therapeutics has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy NTLA.

  • StrongBuy: 18
  • Buy: 4
  • Hold: 6
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the NTLA price?
Analysts Target Price 26.6 104.1%
Intellia Therapeutics (NTLA) - Fundamental Data Overview as of 14 July 2026
Market Cap USD = 1.99b (1.99b USD * 1.0 USD.USD)
P/S = 30.0513
P/B = 3.1986
P/EG = -0.0969
Revenue TTM = 66.1m USD
EBIT TTM = -394.6m USD
EBITDA TTM = -384.6m USD
Long Term Debt = 61.4m USD (estimated: total debt 80.5m - short term 19.1m)
Short Term Debt = 19.1m USD (from shortTermDebt, last quarter)
Debt = 80.5m USD (from shortLongTermDebtTotal, last quarter) (leases 80.5m already included)
Net Debt = -295.5m USD (calculated: Debt 80.5m - CCE 376.0m)
Enterprise Value = 1.69b USD (1.99b + Debt 80.5m - CCE 376.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -394.6m / Interest Expense TTM 0.0)
 EV/FCF = -4.65x (Enterprise Value 1.69b / FCF TTM -363.6m)
FCF Yield = -21.51% (FCF TTM -363.6m / Enterprise Value 1.69b)
 FCF Margin = -550.2% (FCF TTM -363.6m / Revenue TTM 66.1m)
 Net Margin = -597.0% (Net Income TTM -394.6m / Revenue TTM 66.1m)
 Gross Margin = -153.7% ((Revenue TTM 66.1m - Cost of Revenue TTM 167.7m) / Revenue TTM)
Gross Margin QoQ = 85.37% (prev 73.87%)
Tobins Q-Ratio = 2.23 (Enterprise Value 1.69b / Total Assets 758.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 80.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -311.7m (EBIT -394.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.10 (Total Current Assets 466.4m / Total Current Liabilities 76.4m)
Debt / Equity = 0.13 (Debt 80.5m / totalStockholderEquity, last quarter 620.9m)
 Debt / EBITDA = 0.77 (negative EBITDA) (Net Debt -295.5m / EBITDA -384.6m)
 Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -295.5m / FCF TTM -363.6m)
 Total Stockholder Equity = 689.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.23% (Net Income -394.6m / Total Assets 758.8m)
RoE = -57.27% (Net Income TTM -394.6m / Total Stockholder Equity 689.0m)
RoCE = -52.58% (EBIT -394.6m / Capital Employed (Equity 689.0m + L.T.Debt 61.4m))
 RoIC = -44.65% (negative operating profit) (NOPAT -311.7m / Invested Capital 698.1m)
 WACC = 12.43% (E(1.99b)/V(2.07b) * Re(12.93%) + D(80.5m)/V(2.07b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.91 | Cagr: 12.75%
 [DCF] Fair Price = unknown (Cash Flow -363.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: 59.30 | Revenue CAGR: 12.39% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.79 | Chg30d=+0.91% | Revisions=+64% | Analysts=16
EPS next Quarter (2026-09-30): EPS=-0.78 | Chg30d=+1.19% | Revisions=+64% | Analysts=16
EPS current Year (2026-12-31): EPS=-3.14 | Chg30d=+0.81% | Revisions=+69% | GrowthEPS=+17.6% | GrowthRev=-11.8%
EPS next Year (2027-12-31): EPS=-1.72 | Chg30d=+6.29% | Revisions=+71% | GrowthEPS=+45.1% | GrowthRev=+354.5%
[Analyst] Revisions Ratio: +79% (up=45, down=4)